← Eichor
Study identifier: NCT05204472 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Thalamic-Burst-DBS for Neuropathic Pain

Condition: Central Post-stroke Pain · Neuropathic Pain  ·  Sponsor: Insel Gruppe AG, University Hospital Bern

PhaseNA
Planned participants20
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Central post-stroke pain (CPSP) is a neuropathic pain syndrome and one of the major sequelae after ischemic or hemorrhagic cerebral stroke. Recently, a modified stimulation paradigm has been developed in the field of spinal cord stimulation (SCS) for a variety of neuropathic pain disorders. To date, this stimulation paradigm has not yet been evaluated systematically for deep brain stimulation to treat neuropathic pain disorders. The purpose of this clinical investigation is to investigate if Burst-DBS of the thalamus is more effective compared to classical continuous low-frequency stimulation DBS to reduce the subjective pain intensity in patients with chronic neuropathic pain after stroke or in patients with neuropathic facial pain.

This description comes directly from the study's public registry record.

Talk to the study team

Andreas Nowacki, MD  ·  +41 31 6320014  ·  andreas.nowacki@insel.ch

Söll Nicole  ·  +41316323164  ·  nicole.soell@insel.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Dep. of Neurosurgery, Bern University HospitalBern, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05204472